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PIIETRA, SPEN?CER AND) SHUBIK (1959) reported the induction of maligilailt
lymplJ)oma (lymphocytic leukaemia) and lung adenomas in Swiss mice injected
sulbcutaneollsly when new-born (less than 24-hour old), with 30 jig. 9,10-dimethyl-
1,2-henzanthracene (DMBA) suspended in 1 per cent aqueous gelatine. Later,
Stich (1960) obtainedl a similar result using a 60 ,lg. dose of DMBA.
W11e were interested in the report of Pietra et al. (1959) for two reasonis. Firstly
we were anxious to discover whether cell-free filtrates prepared from malignant
lymnphoma induced by the injection of a carcinogen could themselves be passed to
other mice bv mea,ns of cell-fiee filtrates (e.g. G(ross, 1957), and this method of
chemical induction of lymphoma seenmed ver-y suitable. Secondly, the method
described bv Pietra et, al. (1959) offered the possibility of a highly sensitive test
for carcinogenic activity. In the latter coninection it was important to find out
whether other strains of mice would respond in the same way as the Swiss nlice
used by Pietra et al., and also whether leukaemiia and lung tumours could te
induced; bv the injection of other carcinogens, I)oth strong and weak, into new-
b)orn mice.
At the time that the present paper was ready for submissioni a second paper
by Pietra and his colleagues (Pietra, Rappaport and Shubik, 1961) was pub-
lishedl. The latter extende(d tlheir earlier findings in four directions: firstly
thev confirmed their original observation with DMBA. secondly they tested 4
othercarcinogens, 3,4-benzopyrene, 20-nvmthylcholanthrene, 1,2:5,6-dibenzanthra-
ceiie, aI)d urethane by the same method; thirdly they compared the sulb-
cutanieouis and intraperitoneal routes of administration for each of the 5 carcin-
ogens : and fourthly thev reported the induction of tumours at sites other than
the lung and the lymphatic system. Even more recently Fiore-Donati et al. (1961)
have recorded similar findings in an experiment in which new-born mice were
injected with urethaie and Kelly and O'Gara (1961) have obtained similar
results w-ith 20-methylcholanthrene and 1,2:5,6-dibenzanthracene.
Work reported in the present paper confirms and extends the studies of Pietra
and his colleagues. Two inbred strains of mice were used, and their response to
DMBA compared. Induction of tumours of many sites, including those mentioned
by Pietra et al. (1961), is described. The testing of cell-free filtrates prepared fron
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carcinogen-induced malignant lymphoma will be the subject of a later com-
munication.
MATERIAL AND METHODS
Mice. "CBA " and " 101 " inbred strains, both obtained originally from the
MRC Radiobiological Research Unit, Harwell, were used (for further details see
,Snell et al., 1960). Metal cages were used throughout the experiment. Diet 41B
and water were provided ad libitumn.
Chemicals. 9,10-dimethyl-1,2-benzanthracene (DMBA) was obtained from
L. Light & Co.; gelatine from British Drug Houscs; and croton oil from Stafford
Allen and Co.
Preparation and admninistration of DMBA/gelatine suspension.-The methods
of preparation and administration described by Pietra, Spencer, and Shubik
(1959) were followed precisely. Thirty 'g. DMBA suspended in 15 Iul. of 1 per cent
aqueous gelatine wxere injected subcutaneously in the interscapular region into
test groups ofboth strains. One per cent aqueous gelatine alone was injected into
a control group of the CBA strain. Untreated mice of both strains were also kept
as controls. The general layout of the experiment is shown in Table I.
Litters which averaged 5-6 mice each were allotted randomly to test and con-
trol series, until groups of the required size were formed (7 to II litters per group
see Table I).
All mice were less than 24 hours old when injected.
Subsequent conduct of the experiments.-Litters were housed separatelv until
weaning, at which time the mice were numbered on the ears and re-housed in
boxes of 8 to 10 according to group and sex. A proportion of the mice failed to
survive until weaning (Table I), but it was not possible to examine post mortem
any of those which died.
After re-housing the mice were carefully examined, at first once weekly and,
from the 10th week onwards, twice weekly until they were 1 year old, for evidence
of malignant lymphoma, tumours of other sites, and other lesions. Sick mice were
killed and examined post mortem, and at the end of the year all the survivors
were killed and similarly examined.
Routine post mortem examination included a close scrutinv of the stomach
wall after fixation by dilatation with formal saline.
RESULTS
In both strains, groups injected with DMBA survived less well, and had a
higher incidence of malignant lymphoma, lung tumours, skin tumours, tumours
of the fore-stomach, and tumours of other sites, than uninjected mice or mice
injected with suspending medium only. These differences are considered below
under separate headings.
Survival
It is doubtful whether treatment with DMBA had any unfavourable effect on
survival during the first month of life (see Column 6 in Table I). The overall
higher death rate during this period in CBAs as compared with " 101 "s, was
probably due to the higher incidence of litter-eating in the former. This was
common in our CBA colony at the time that the experiment was begun.
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]Deaths between the end of the first month and one year were far more lnullmer-
otis in the IDMBA-treated groups of both strains than in the control groups (for
details see column 7 in Table I). The commonest causes of death during this
period were malignant lymphoma of the stem-cell type (Pietra et al., 1961) in-
vTolving the thymus, and tumours of the Jung. Six DMBA-treated CBAs, and 9
DMBA-treatedc 101 "s died from lymphoma, and 2 mice of each strain from
nultiple, large, and/or malignant, lung tumours. Three DMBA-treated CBAs anid
I DMBA-treated " 101" died without tumours of any site. No tumours were
seen in either of 2 c9ntrol mice (one from Group 2, and one from Group 5). No
post mortem examination was possible in 15 mice (Table I). Combining the
results from the two strains: 37/84 DMBA-treated mice died between 1 molnth
and 1 year, whereas only 5/110 untreated or control-injected mice did so.
MJalignfant lymphoma with thtymic invrolcemnent
The earliest clearcut difference between the l)MBA-treated and the conitrol
groups was in the incidence of malignant lymphoma. As shown in Tables I and II
a total of 15 cases were seen in the two groups treated with DMBA. Only one
vrery late case was seen in the control groups. This was in an untreated 101
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mouse, and was discovered at routine post mortem at one year. It was ofa different
histological type from the other cases (vide infra). Table II shows that the cases
of malignant lymphoma were distributed randomly between the DMBA-treated
litters. It is doubtful whether there was a real sex difference in incidence in either
strain ; in fact, the apparent differences were in the opposite direction in the two
strains. The total incidence was 20 per cent of " 101 " mice, and 15-4 per cent
of CBA mice, alive at 1 month, but this slight difference was associated with a
striking difference in average induction time; 16-5 weeks in " 101 "s, and 26
weeks in CBAs. The latter difference was analysed by the " t " test and found
significant (P < 0-01). This analysis, however, did not take into account the
possibility that some of the DMBA-treated mice which died without post mortem
may have had malignant lymphoma. This is unlikely, because they were not
thought to have thymic tumours or enlarged lymph nodes when examined a few
days before death, and because in both strains the average time of death of the
* Death from malignant Iymphoma
O Death from causes other than malignant lymphoma
? Cause of death not ascertained because of decomposition
* 0 * 6 deaths atan average of 26-0 weeks
CBA strain 0 - - ? 4 38- 0 -
* ? 0? 0 0?
weeks 10 20 30 40 50
0 0 9 deaths at an average of 16-5 - -
101 strain .. ? ? 0 ? * 00*00 * 0 0 00? 0 ? - -----3332 - -
weeks 10 20 30 40 50
FtG. 1. Comparison of induction-time of inalignant lymnphoma in CBA and " 101 "-strain
mice after the injection of 30 ,ug. DMBA when newly born. This figure shows that deaths
from unascertained causes occurred, for the most part, after the )eriod during which
malignant Ivmnphoma appeared.
unexamined mice was considerably longer than that of the mice with lymphoma,
and similar to that of mice dying without it (Fig. 1).
All the cases of malignant lymphoma which arose in the DMBA treated mice
were of the histological type referred to by Pietra et al. (1961) as ' stem cell ".
In all of them there was gross enlargement of the thymus, so that it filled more
than half the thoracic cavity, and an accompanying enlargement of some or all
the lymph glands (axillary, inguinal, cervical, lumbar, pararenal, mediastinal, etc.).
The spleen, on the other hand, was usually ofnormal size, and the liver always so.
The malignant lymphoma seen in the control untreated " 101 " mouse had a
different distribution throughout the lymphatic system, and appeared quite
different microscopically. There was slight enlargement of the left lobe of the
thymus and more marked enlargement of the left pararenal lymph gland. The
mesenteric lymph gland and spleen were also moderately enlarged, but the lymph
glands in the neck, axillae, inguinal, and lumbar regions were of normal size.
Microscopically the enlarged glands and thymus consisted predominantly of
histiocytes with abundant eosinophilic cytoplasm. Mitotic figures were plentiful.
The disease in this mouse was considered to be of the type referred to by Pietra
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et al. (1961) as "histiocytic". No cases of lymphoma of the "lymphocytic"
type, as described by Pietra and his colleagues, were seen.
Lung tumours
In both strains, mice treated with DMBA developed multiple benign, and
occasional malignant, tumours of the lungs. By comparison, untreated mice of
both strains and gelatine-injected CBAs developed a negligible number of such
tumours, none of them malignant.
Pulmonary tumours were certainly present in several of the mice dying early
from mnalignant lymphoma. However these were not counted because of the
difficulty of distinguishing, except by microscopic examination, between adenomas
and metastatic lymphomatous deposits. Apart from these, 4/10 DMBA-treated
mice dying before they were 1 year old, had lung tumours.
TABLE III.-Incidence of Lung Tumours 52 WeeksAfter Injection of 30 ,tg. DMBA
into New-born CBA and
" 101 "-strain Mice
Mice Average Average
Mice with lung diameter
alive lung tumours of largest
at 52 tumours /mice Total per mouse tumour
Group) Strain Treatimient weeks* examined tumours examined (mm.)
1 . CBA DMBA/Gelatine 21 16/18 222t 122 1- 8
2
.
,
Gelatine 26 0/25 0
3 .. None 39 3/39 6 016 1 2
4 101 DMBA/Gelatine 26 24/25 327t 13-1 3-4 . ,, .
None 40 61/40 10. 025 1 3
* Three mice from Group 1, and one each from Groups 2 and 4 died during the 52nd week anld
were too decoinposed when found for post mortem examination.
t One malignant adenocarcinoma.
I Five of these mice, bearing 9 of the 10 tuinours come from two litters and were housed together
fromii weaninig till death. It is possible that contamination with a carcinogen was responsible.
Table III shows the incidence of lung tumours in mice which survived for one
year and were then killed. The DMBA-treated mice of both strains had an average
of 12-13 tumours per mouse, whereas the incidence in the control groups was
less than 0 3 tumours per mouse. The strains appeared to differ in their response
toDMBA in that the average size of the largest tumours in the " 101 "mice was
alJmost double that of the largest tumour in CBA mice. This difference was analysed
by the
" t
" test and found to be significant (P < 0 01). In fact not only the
largest, but all the lung tumours in
"101
" mice tended to be larger than those
in CBAs, and there can be no doubt that if records of the sizes of all tumours were
available for comparison the difference would be even more significant.
Histologically all the tumours were of the well-known adenomatous type. Two
of the tumours, one in a CBA mouse and one in a " 101 ", were adherent to the
chest wall and had metastased to the mediastinum and upper surface of the
diaphragm. Apart from these undoubtedly malignant tumours there were others
which showed microscopic evidence of infiltration of surrounding pulmonary
tissue.
There was no sex difference in the lung tumour response of " 101 "-strain mice
to treatment with DMBA: 16 males which survived the year had an average of
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13'2 tumours per mouse, against an average of 12-8 in 9 females. No comparison
was possible in the case ofCBAs since only 2 males ofGroup 1 came to post mortem
at 52 weeks.
Tumours of the skin
Benign papillomas and sebaceous adenomas of the skin were seen in 1 out of
18 CBA and in 7 out of 25 " 101 " DMBA-treated mice which were examined
post mortem at 52 weeks. All arose between the 35th and 52nd weeks, and the
majority were on the head and face. One of the sebaceous adenomas is shown in
Fig. 2. No skin tumours were seen in 104 control mice examined at the same time.
No malignant skin tumours were seen in any group.
Tumours and telangiectasia of theforestomach
Close examination of the stomach was not at first included in the routine post
mortem examination. However, when the first batch of mice from Group 4
(DMBA-treated " 101 "s) were killed and examined, papillomas and bright red
patches were seen in the wall of the forestomach. Thereafter all stomachs were
carefully examined, after distension with fixative. Only tumours of 1 mm. diameter
and over were counted, and special care was taken in interpreting irregular pro-
jections in the vicinity of the ridge between forestomach and glandular stomach.
The results are shown in Table IV.
TABLE IV.-Papillomas and Telangiectases in the Forestomachs of 52-week old (1BA and
101 "-strain Mice Injected when New-born with 30 ,ug. DMBA
Number
of mice Mice
examined with
for papillomas Papillomnas Mice
lesions of of 2 mm. with Total
fore- fore- Total diameter telangiec- telangiec-
Group Strain Treatment stomach stomach papillomas or more tases tases
1 .CBA. DMBA/Gelatinc 22 2 2 1
2 , . Gelatine 23 0 0 0 0 0
3 ., . None 38 0 0 0 . I 1
4 .101. DMBA/Gelatine 20 16 . 64 7 6 15
5 . None 30 0 0 0 () 0
Papillomas were seen in DMBA-treated mice of both strains but not in any
of the control groups. The incidence was far higher in the " 101 " than in the
CBA strain. Most of the papillomas were about 1 mm. diameter but a few ex-
ceeded 2 mm. diameter (Fig. 3). There were no malignant tumours.
The occurrence of bright red patches in the wall of the forestomach has not
to our knowledge been reported previously. They were seen in both strains
(Table IV). The majority were circular and some were as large as 2-5 mm. diameter.
Six of these lesions were examined microscopically: they were found to consist
of groups of dilated capillaries, in fact typical telangiectases (Fig. 4). In several
of the mice which had these lesions, and in some that did not, there were macro-
scopically similar lesions in the proximity of one or more of the Peyer's patches
of the small intestine. Unfortunately no precise records were made of the latter
in the present experiment. However, vascular lesions of the gut wall are not
uncommon in mice treated with DMBA or urethane as young adults (unpublished
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data). Microscopic examination of the latter has shown them to be either telan-
giectases, or haemorrhages possibly derived from pre-existing telangiectases.
Hepatic tumours
Three mice in Group 1, 2 in Group 3, and 1 in each of the other 3 groups had
parenchymal-cell liver tumours. Clearly this difference in incidence between the
DMBA-treated and control groups was minimal. However it was interesting that
the three CBA mice ofgroup 1 had multiple (more than 10) tumours each, whereas
the 3 control CBAs from Groups 2 and 3 had 2, 1 and 1 tumours respectively.
Similarlvy the mouse in Group 4 with liver tumours had 4 of them, whereas the
mouse from Group 5 had only 1.
Histologically, several of the tumours showed cytoplasmic inclusions similar
to those described by Burns and Schenken (1940) and Craigie (1955). In viewof
the sex difference observed by these authors in C3H mice, it is of interest that 7
out of the 8 mice reported here were males. The remaining mouse, a gelatine-
injected control of Group 2, was a virgin female, exactly 1 year old when killed.
The tumour in this mousewas 5 mm. in diameter and of typical gross appearance:
it was not examined histologically.
T'umoirs of other sites
Eleven mice, all of which had been treated with DMBA, had tumours of other
sites. These are listed in Table V, and four of them are illustrated in Fig. 5-8.
Since only one or two examples of each kind of tumour were seen it is not
proposed to describe them in detail.
Patpillonephritis
Naked eve evidence ofthis disease, consisting ofswelling, pallor, or calcification
of the renal papilla, and cicatrisation of the renal cortex, was observed in 9 out of
26 DMBA-treated" 101 "-strain mice, and in 20 out of 39 untreated control mice
of the same strain, killed when 1 year old. No cases of the disease were seen in
CBA mice.
EXPLANATION OF PLATES
Lesions seen in iice injected when less than 24 hours old with 30 ,ug. DMBA in I per cent
aqueous gelatine. and killed when 52 weeks old. Stained H. and E.
FIG. 2. Sebaceous adenoma from skin of abdominal wall of a " 101 ". x 48.
FIG. 3.- Papilloma of wall of forestomach of a CBA Y. x 35.
FIG. 4.-Telangiectasis in wall of forestomach of a CBA Y. A group of grossly dilated capil-
laries are seen beneath the keratinized squamous epithelium. The wide gap between the
dilated vessels and the muscle layers is an artifact. x 70.
FIG. 5. Granulosa-cell tumour of ovary from a CBA. x 370.
FIcG. 6. Cortical adnoma in the kidney of a " 101 " <. x 65.
FIG. 7. Malignant haemangiomiia infiltrating subcutaneous and muscle layers of thigh and
abdominal wall of " 101 " Y. Remnants of voluntary muscle are seen. Parts of this
tumour were more cellular and mitotically active. x 330.
FIG. 8. Tumour from parotid gland of a " 101 " d. Opinion was divided as to the nature of
this tumour. The absence of cross-striations in a P.T.A. stain failed to support a diagnosis
ofrhabdomyosarcoma and the high mitotic rate and arrangement ofP.T.A.-positive material
in the cytoplasm, as bunches of thin threads, did not fit the diagnosis of oxyphilic granular
cell adenoma (onkocytoma). The final diagnosis lay between the latter and leiomyosarcoma.
x 370:
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TABLE V. M1iscellaneous Tumours seen in 52-week old CBA and " 101 "-strain
Mice, Injected when New-born with 30 pg. DMBA (Excluding Malignant
Lymphoma and Tumours of Lung, Skin, Stomach, and Liver)
Mice
examined
at 52 Figure
Groul) Straini Treatment weeks Miscellaneous tuniours Number
1 CBA DMBA/Gelatine 18 Carcinoma ofadrenal cortex (1 case) 5
Granulosa-cell tumour of ovarv (2
cases)
2 .. Gelatine 25 None
3 ., None 39 None
4 D11 DMBA/Gelatine 25 Cortical adenorna ofkidney (2 cases, 6
one with 2 adenomas)
Fibrosarcoma in subcutaneous tis-
sues of ear (1 case)
Haemangioma (3 cases, one in sub-
cutaneous tissues of neck, one in
uterus, and one highly malignant
tumour involving thigh and body
wall) 4
Myeloid leukaemia (1 case)
' Leiomyosarcoma of parotid gland . 8
(I case)
.) . ,, . None . 40 . Noine
The occurrence of papillonephritis in " 101 "-strain mice has been commented
upon previously (Roe et al., 1959). The present observation confirms our previous
impression that treatment with DMBA does not materially affect the incidence
of the disease (Roe and Peirce, 1960).
DISCUSSION
1. Significance of experimental results
In general our experimental findings confirmed those of Pietra et al. (1959,
1961), Stich (1960), Fiore-Donati et al. (1961), and Kelly and O'Gara (1961), but
several new observations were made.
Injection of 30 pug. DMBA subcutaneously into new-born mice had no pro-
nounced effect on survival up to the age of weaning, but adversely affected it to a
significant degree between the ages of 1 month and 1 year. During the latter period
malignant lymphoma (stem-cell type) and multiple lung tumours accounted for
about halfthe deaths, but there was also an increased death-rate from causes other
than neoplasia. Cases of malignant lymphoma were seen in the DMBA-treated
groups of both strains of mice: all cases arose between the 10th and 32nd weeks,
a finding closely similar to that in the earlier studies referred to above. The inci-
dence was similar in the two strains (20 per cent in " 101 "s and 15-4 per cent in
CBAs), but the time of appearance was significantly earlier in the " 101 " strain.
There was no evidence that susceptibility differed between litters of the same
strain.
Multiple pulmonary tumours were seen in DMBA-treated mice of both strains.
Most of these were apparently benign, but two were manifestly malignant. At
one year the average number of pulmonary tumours per survivor was similar in
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the two strains, but there was a significant strain difference in the average size
of the largest adenoma in each mouse. The fact that all lung tumours (not only
the largest) tended to be larger in the ' 101 " strain could be explained by earlier
appearance in this strain, as in the case of the malignant lymphomas. However,
a recent observation by Rogers (1960) throws doubt on this view: he found that
equal-sized pieces of small and large lung tumours, when transplanted to the ears
of genetically compatible host mice, grew at different rates, the latter growing
faster than the former. This would suggest that in the present experiment the
lung tumours in the " 101 " strain had a higher growth-rate than those in the
CBA strain. Further experiment is required to settle this point.
The results as a whole indicated that the CBA strain is less responsive to the
carcinogenic action of DMBA than the " 101 " strain. It was therefore sur-prising
that the final incidence of lung tumours was so similar. Of course the tumour
counts refer only to macroscopically visible surface adenomas, and the incidence
in the two strains might have appeared quite different if smaller and more deeplv
situated lesions had been taken into account. Further, the comparison was made
after the arbitrary period of one year. If this period had been shorter or longer
a difference in tumour incidence might have been seen. The period of onset of
malignant lymphomas was complete at the 32nd week. We do not know whether
the appearance of lung tumours was confined to a definite period, or continlued
throughout life ; and, unfortunately, the very recentlv reported experiments of
Kelly and O'Gara (1961) were not carried on long enough to answer this question.
In some ways the data on size and incidence of tumours presented here suggests
that the former is true. This is a fascinating problem which does not seem to
have been adequately studied (see review on pulmonary tumours in experimental
animals by Shimkin, 1955).
In our experiments there was no definite correlation between treatment witlh
DMBA and incidence ofhepatomas, although it was curious that in DMBA-treated
mice they were usually multiple, while in controls two was the most seen in anv
one mouse. In the experiments of Pietra and his colleagues occasional hepatomas
were seen in carcinogen-treated mice, but none in controls. More recently, in a
preliminary report, Liebelt, Yoshida, and Gray (1961) describe a striking enhance-
ment ofthe incidence ofhepatomata in C3Hfmice injected with urethane when less
than 24 hours old but not when 6-8 weeks old. The presence of cytoplasmic
inclusions, similar to those described by Burns and Schenken (1940) and Craigic
(1955), in the hepatomas of both DMBA-treated and control mice in the present
experiment suggests that DMBA was not the only causative agent. It mav be
that the administration of carcinogen to new-born mice enhances the effect of
another agent.
The induction of skin tumours bv administration of DMBA to suckling mice
was perhaps not surprising, in view of certain recent observations. Rous (1956)
observed skin tumours in untreated mice, and attributed them to the fact that the
mice had been bred in wooden cages preserved with creosote. Poel and Kammer
(1957), Lijinsky, Saffiotti, and Shubik (1957), Shubik, Spencer, and Della Porta
(1957) and Boutwell and Bosch (1958) conducted experiments which confirmed
that relatively slight exposure of infant or adult mice to creosote led to the in-
duction or initiation of skin tumours. The fact that most of the tumours seen in
the present experiment arose on the face and head fits in with a previous observa-
tion of one of us (Roe, 1956) that the skin tumours which arise 36 weeks or more
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after the application of 300 ,ug. DMBA to the dorsal skin of 8-week old mice are
also predominantly on the head and face.
Papillomas of the forestomach were not noted by Pietra and his colleagues.
However such tumours would be overlooked if routine post mortem examination
did not include dilatation of the stomach with fixative and examination of the
lining when fixed. The discovery of papillomas in this site was not altogether
surprising, in view of the recent demonstration by Bock and King (1959) of the
relatively high sensitivity of the forestomach epithelium to tumour induction.
The telangiectasia of the stomach wall is also a new observation. Dilatation
of vessels and haemorrhages in the wall of the small gut, particularly in the
proximity of Peyer's patches, in mice treated as adults with DMBA or urethane
have been seen by us in previous experiments, but we do not recall seeing similar
lesions in the forestomach. Unfortunately no record of the frequency of intestinal
telangiectases and haemorrhages was made in the present experiment, though it
is known that they occurred. There was no tendency for papillomas and telan-
giectases of the forestomach to occur at the same site.
Several other miscellaneous tumours, in particular granulosa-cell tumours of
the ovary, and haemangiomata of the various sites, occurred both in the present
experiment and in those of Pietra et al. (1961). There can be little doubt that
they resulted from carcinogen treatment. The induction of a carcinoma of the
adrenal cortex, of an unusual tumour of the parotid gland (? leiomyosarcoma)
(Fig. 8), and of several adenomata of the renal cortex, by a chemical carcinogen
are observations which may have importance in their own right.
Search through the literature listed by Hartwell (1951) and Shubik and
Hartwell (1957) revealed no examples of induction of any of these tumours by
carcinogenic polycyclic hydrocarbons, except the induction of renal tumours bv
the introduction ofmassive doses directly into the kidney (Ilfield, 1936; Oberling,
Sannie and Guerin, 1937; Esmarch, 1942). Even this drastic technique sometimes
yielded negative results (e.g. Oberling et al., 1936; Woglom, 1938). On the other
hand, adenomata of the renal cortex have been repeatedly induced by other
agents, e.g. by polyoma virus in mice (Stanton et al., 1959) and hamsters (Hani
et al., 1960), by another virus in frogs (Lucke, 1952), by oestrogens in male ham-
sters (Kirkman and Bacon, 1949; Horning, 1954), and by X-irradiation in rats
(Koletsky and Gustafson, 1955).
Steiner (1942) introduced carcinogenic polycyclic hydrocarbons into the salivarv
glands of mice, rats, guinea-pigs, and rabbits. In all species except the rabbit he
observed a variety of tumours including squamous carcinomas, acantho-adeno-
carcinomas, adenocarcinomas, spindle-cell sarcomas, and cavernous haemangio-
sarcomas. However he did not see any tumours similar in microscopic appearance
to the one in the present experiment (Fig. 8), and no such tumours are recorded
in experiments prior to 1942 (for reference see Steiner, 1942). It is possible that
some of the parotid gland tumours seen by Bauer and Byrne (1950) were in fact
of this histological type. Like Steiner they induced their tumours by the intro-
duction of the carcinogen (20-methylcholanthrene) directly into the salivary gland.
The parotid tumours induced by the polyoma virus (Law, Dunn and Boyle,
1955: Salaman, 1959) are histologically quite different from the tumour seen in
the present experiment.
The absence of tumours at the site of injection of DMBA is somewhat sur-
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prising, and suggests rapid diffusion, which may prove one of the advantages of
the teehnique when the method is considered as a possible general test for carci-
nogenicity (see next section).
2. The possibility of the development of a sensitive, generally applicable, broad-
spectrum test for carcinogenic action
The armoury oftests available for detecting carcinogenic activity is potentially
large, but most such tests involve long periods of treatment and/or observation
before a positive result can be expected or a negative one accepted. A quick and
sensitive screening test for carcinogenic activity is being sought today by many
with almost alchemistic fervour. Several have been proposed (e.g. the sebaceous
gland suppression test ofSuntzeff, Cowdry and Croninger, 1955, and the newt test
of Neukomm, 1956); however, after brief periods of popularity, such short-cut
methods have been found inadequate as substitutes for a battery of long-term
tests.
The extraordinary sensitivity of new-born mice to the carcinogenic action of
a single 30 ,tg. dose of DMBA given subcutaneously, as first demonstrated by
Pietra et al. (1959), suggested to us the possibility that this technique might lead
to the development of a relatively quick and sensitive test for carcinogenic action.
The subsequent studies of Pietra et al. (1961), Stich (1960), Fiore-Donati et al.
(1961), Kelly and O'Gara (1961), and those reported here, are encouraging.
The relevant facts are these:-
(1) All strains of mice so far tested have developed multiple tumours in re-
sponse to treatment with a known carcinogen, whilst very few tumours have been
seen in comparable controls treated with solvent only. Immediate mortality was
low.
(2) 4 carcinogenic polycyclic hydrocarbons gave clear-cut positive results,
and so did urethane, a carcinogen of an entirely different class.
(3) The induction of tumours of the forestomach, skin, kidney, ovary, etc.,
clearly indicate that the test material spreads all over the body and that the test
is not dependent, as most others are, on the sensitivity of one tissue.
(4) In the case of malignant lymphomas there is evidence of an upper age
limit after which this type of neoplasm does not appear. For the Swiss mice used
by Pietra et al. (1961), and for the CBA strain used by us, this upper limit appears
to be around the 33rd week, and for the " 101" strain some 10 weeks earlier.
Thus it may be possible to establish an acceptable " negative " after a definite
period of observation.
(5) The sensitivity of lung tissue to tumour induction is perhaps the most
striking feature of this test. A significant positive would certainly have been
scored using a much lower dose ofDMBA than 30 ,tg. Thus there is hope that very
weak carcinogenic activity may be detectable. Pietra et al. (1961) reported a
37.5 per cent incidence of pulmonary tumours in mice treated with only 40 ,tg.
urethane, a much smaller dose of this substance than any previously shown to
be effective.
(6) Apart from the sensitivity of the test, if generally applicable it will prove
very economical. Each mouse is under experiment from the day of its birth,
and no space has to be set aside for animals too young for use in experiments.
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A test of this kind can be regarded simply as an improvement on that de-
veloped by Andervont and Shimkin during the years from 1935 onwards. Appre-
ciating the extreme sensitivity of mouse pulmonary tissue to the carcinogenic
effect of a variety of agents, they injected a standard dose (0.25 mg.) of the test
substance intravenously into young adult mice, and recorded the percentage of
mice which developed lung tumours. Later the multiplicity and size of induced
tumours were taken into account. But the difficulty remained that the test had
no clear end-point (see Shimkin, 1955, p. 240). The longer the mice were kept the
higher the proportion of tumour-bearers and the number of tumours, in both test
and control mice. But when newborn mice are injected, it appears that malignant
lymphoma induction has an end-point at about 23 to 33 weeks, depending on the
strain, and it is possible that there is an end-point tolung-tumour induction also
(videsupra, p. 524). This method enables observations to be made earlier, and if
there is an end-poin-t it is brought forward to a time when it is easier to detect.
Since Andervont and Shimkin made their fundamental studies many changes
have taken place in animal husbandry. The importance of contamination of mice
during the neonatal period with small amiounts of carcinogens has been under-
lined by recent studies on the use of creosote-treated wooden mouse boxes
(Boutwell and Bosch, 1958; Roe, Bosch and Boutwell, 1958). Since the use of
metal cages for all breeding and experimental mice became general, the incidence
of so-called "spontaneous " lung tumours in mice has declined. There is therefore
a real possibility that an end-point to the period during which these tumours
appear after exposure to a single early carcinogenic stimulus could now be
demonstrated.
The next stages in the development of the test include the assessment of
carcinogens of different chemical types and of weak or borderline carcinogens,
dose-response studies, and the search for even more sensitive strains of mice, or
other species. Clearly many workers in this general field are thinking along these
lines. Already data on dose-response relationships are becoming available (e.g.
Kelly and O'Gara, 1961), and other experiments are in progress in several research
centres.
3. The bearing of these results on imnmunological theories of carcinoyenesis
According to a theory which has been put forward in various forms, an immune
reaction is one component ofthe carcinogenic process (e.g. Green, 1961). A chemical
carcinogen is supposed to form a complex with a specific cell protein. This com-
plex, it is assumed, is antigenic, and the antibody formed to it acts on both the
altered and unaltered protein, creating a state of stress in the treated tissue.
Cells then appear by mutation which are deficient in the specific protein, and these,
it is thought, will have a proliferative advantage over their neighbours.
This theory, to which the foregoing brief account does less than justice, re-
quires that the antibody-forming apparatus shall be competent while stimulating
antigen is present. It has been shown that when an antigen is introduced into a
foetal or new-born mouse, and persists in the body, no antibody is formed to it,
and a state of specific tolerance develops (for review see Medawar, 1960).
If, as seems probable, the carcinogen-protein complex is formed quickly, the
injection of a carcinogen into a new-born mouse ought to give rise not to antibody
formation, but to immune-tolerance. Rapid multiple tumour induction by this
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imiethod suggests therefore that carcinogenesis is not necessarily dependent on aln
inmune mechanism.
The position is conmplicated by the facts that only the carcinogen-proteiin
complex is assumed to be antibody-inducing, but that the unaltered protein reacts
with the antibody formed in response to the complex. To produce lasting tolerance
it has been shown that the antigen must persist (Smith and Bridges, 1958:
MVlitchison, 195t9). It is true that the carcinogen, as well as its protein complex,
is probably eliminatedl fairly rapidly (in a few days to a few weeks, see Heidel-
berger and Wiess, 1951) but it is impossible to say whether the continued pre-
sence of the antibodv-reactive original protein would be adequate to maintain
the tolerance originally induce(d by the carcinogen-protein complex. But even if it
were not, since it is a " self " protein, it would not itself stimulate antibody pro-
(luction once the age of immune non-competence was passed.
It does not seem possible to avoid the conclusion that carcinogenesis by in-
jection of the new-born is incompatible with this immunological theorv of
carcinogenesis.
SUMMARY
1. Mice of two strains, CBA and " 101 ", were injected when new-born with
:30 ,g. 9,10-dimethyl-1,2-benzanthracene (DMBA) in 1 per cent aqueous gelatine,
and thereafter examined regularly for tumour development. At the end of one
Year all the survivors were killed and examined post mortem. Comparable unI-
treated mice of both strains, and CBA mice injected with aqueous gelatine, were
observed.
2. DMBA had no definite effect on survival before weaning, but adversely
affected it between 1 month and 1 year. Malignant lymphoma (stem-cell type)
and tumours of the lung were commonest causes of death. There were no deaths
from tumours among the control groups.
3. In the DMBA-treated mice killed after 1 year, tumours of the following
sites were seen lung (average of over 12 tumours per mouse), skin, forestomach,
liver, ovary, adrenal, kidney, subcutaneous tissues, parotid gland, and uterus.
Occasional tumours of liver and lung, and one malignant lymphoma of the histio-
cytic type, were the only tumours seen in control mice.
4. Telangiectases were seen in the wall of the forestomach of 8 DMBA-treated
nice and of 1 control mouse.
5. In general the 101 " strain was more sensitive to the carcinogenic action
of DMBA: malignant lymphoma, and tumours of skin, forestomach, and miscel-
laneous sites were more frequent in this strain. Malignant lymphoma appeared
after a significantly shorter latent interval, and the lung tumours seen in mice
killed after 1 year were significantly larger.
6. The results are compared with those ofprevious workers, and the possibility
of developing a highly sensitive broad-spectrum test for carcinogenic action based
on the injection of test substances into newborn mice is discussed.
7. The implications of these results for certain immunological theories of
carcinogenesis are considered.
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